FDA Guidance on Risk-based Monitoring While Improving Data Quality, New Life Science Webinar Hosted by Xtalks

Share Article

Xtalks presents an exciting live webinar on Monday September 30, 2013 at 11:00am EDT on new regulations in RBM and data collection.

News Image

The recent FDA Guidance stresses that Risk-Based Monitoring (RBM) is part of a high-quality study, and that upfront input into the study design is an optimal approach to achieving high quality results, which may increase both patient safety and overall data quality. Critical components for successful delivery include a well-designed protocol and the ability to leverage technology to monitor site and data quality.

Mr. Dan White, Vice President of Global Operations at Quintiles, will be joined by Dan Ballard, Senior Director of Data Quality, to explain the impact of the FDA Guidance on clinical development, how Data-driven Trial Execution can enhance patient safety and data integrity, and, by using technology with enhanced processes as part of an RBM approach, data quality can be improved.

For more information about this event or to register, visit: http://xtalks.com/fda-guidance-on-risk-based-monitoring.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Client Services
Xtalks
+1 (416) 977-6555 227
Email >
Visit website